Good evening :)
Place Order
Add to Watchlist
Home
Portfolio
Search
GoldGold
More

Novartis India Ltd

NOVARTIND

Novartis India Ltd

NOVARTIND
Health CarePharmaceuticals
SmallcapWith a market cap of ₹2,452 cr, stock is ranked 1,068
Moderate RiskStock is 2.66x as volatile as Nifty
972.952.05% (-20.40)
972.952.05% (-20.40)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹2,452 cr, stock is ranked 1,068
Moderate RiskStock is 2.66x as volatile as Nifty
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Good

The stock is underpriced and is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹2,452 cr, stock is ranked 1,068
Moderate RiskStock is 2.66x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
28.733.372.46%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.926.650.51%

Forecast & Ratings

Detailed Forecast 
—
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Novartis India Limited manufactures drugs, medicines and allied products. The Company is engaged in the wholesale of pharmaceuticals and medical goods.

Peers

Compare with peers 
Compare with Peers

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Price Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Revenue Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Earnings Per Share Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Lower than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of -6.96%, vs industry avg of 9.03%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 0.26% to 0.11%

Lower than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 10.47%, vs industry avg of 15.27%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue896.45727.22735.72568.94474.39414.44433.06436.85396.75398.22
Raw Materialssubtract292.88321.33214.55202.60180.49135.88187.26199.34189.98272.19
Power & Fuel Costsubtract4.431.772.561.791.270.530.530.350.18
Employee Costsubtract156.66139.30144.53117.11113.87108.51101.8935.6422.96
Selling & Administrative Expensessubtract123.51126.89122.50107.0380.4355.7357.6148.0033.78
Operating & Other expensessubtract78.1041.8986.0049.8750.1653.9175.1130.3322.91
Depreciation/Amortizationsubtract3.493.592.533.1813.1412.169.656.062.611.54
Interest & Other Itemssubtract0.210.725.531.596.397.684.831.751.490.61
Taxes & Other Itemssubtract38.8834.5179.1634.0018.5619.14-0.1012.0237.6536.48
EPS62.0419.0429.6620.974.088.46-1.5141.8634.5035.40
DPS10.0010.0010.0010.0010.0010.0010.0047.5025.0025.00
Payout ratio0.160.530.340.482.451.18—1.130.720.71
See Costs

EPS and DPS in ₹. Other numbers except Payout Ratio in ₹ cr

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2016

Annual report

PDF
FY 2017

Annual report

PDF
FY 2018

Annual report

PDF
FY 2019

Annual report

PDF
FY 2020

Annual report

PDF
FY 2021

Annual report

PDF
FY 2022

Annual report

PDF
FY 2023

Annual report

PDF
FY 2024

Annual report

PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Valuation

Technical

Forecast

ScreenerCompare valuation on Screener

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Novartis India Ltd29.473.372.46%
Sun Pharmaceutical Industries Ltd45.126.440.75%
Cipla Ltd28.854.440.88%
Torrent Pharmaceuticals Ltd69.1016.690.83%

Price Comparison

Compare NOVARTIND with any stock or ETF
Compare NOVARTIND with any stock or ETF
NOVARTIND
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding70.68%0.00%0.53%0.19%28.60%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep0.24%0.32%0.19%0.19%0.19%0.19%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 1 Mutual Funds holding Novartis India Ltd

Funds (Top 1)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
Bandhan BSE Healthcare Index Fund Direct Plan-Growth

Growth
0.0004%0.06%0.06%91/102 (-1)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividend Cuts

Dividends are the portion of earnings that a company distributes to all its shareholders every year

NOVARTIND has increased or maintained dividend levels over the last 5 years

Dividend Yield

Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 2.46%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹24.58 every year

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateJul 23, 2024

Final
Final | Div/Share: ₹25.00

Dividend/Share

₹25.00

Ex DateEx Date

Jul 23, 2024

Cash Dividend

Ex DateEx DateJul 20, 2023

Special
Special | Div/Share: ₹37.50

Dividend/Share

₹37.50

Ex DateEx Date

Jul 20, 2023

Cash Dividend

Ex DateEx DateJul 20, 2023

Final
Final | Div/Share: ₹10.00

Dividend/Share

₹10.00

Ex DateEx Date

Jul 20, 2023

Cash Dividend

Ex DateEx DateJul 20, 2022

Final
Final | Div/Share: ₹10.00

Dividend/Share

₹10.00

Ex DateEx Date

Jul 20, 2022

Cash Dividend

Ex DateEx DateAug 17, 2021

Final
Final | Div/Share: ₹10.00

Dividend/Share

₹10.00

Ex DateEx Date

Aug 17, 2021

News & Opinions
Earnings
Novartis India standalone net profit declines 13.81% in the September 2024 quarter

Net profit of Novartis India declined 13.81% to Rs 20.41 crore in the quarter ended September 2024 as against Rs 23.68 crore during the previous quarter ended September 2023. Sales rose 10.60% to Rs 87.11 crore in the quarter ended September 2024 as against Rs 78.76 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales87.1178.76 11 OPM %20.6321.47 - PBDT28.1533.08 -15 PBT27.5632.43 -15 NP20.4123.68 -14 Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Novartis India schedules board meeting

Novartis India will hold a meeting of the Board of Directors of the Company on 25 October 2024.Powered by Capital Market - Live

2 months agoCapital Market - Live
💎जैन सा'ब के GEMS... | Novartis India: Sandeep Jain’s Investment Secrets and Future Predictions!
4 months agoZee Business

Novartis India standalone net profit rises 27.05% in the June 2024 quarter

4 months agoBusiness Standard
Earnings
Novartis India standalone net profit rises 27.05% in the June 2024 quarter

Net profit of Novartis India rose 27.05% to Rs 25.74 crore in the quarter ended June 2024 as against Rs 20.26 crore during the previous quarter ended June 2023. Sales rose 1.87% to Rs 92.29 crore in the quarter ended June 2024 as against Rs 90.60 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales92.2990.60 2 OPM %25.9719.17 - PBDT34.2329.33 17 PBT33.6827.77 21 NP25.7420.26 27 Powered by Capital Market - Live

4 months agoCapital Market - Live

RMI Scanner generates new ‘buy’ signal in these 4 stocks; do you own any?

10 months agoMoneycontrol
Novartis India Share Price: हिस्सा बिक्री की खबर से Stock में 11% की तेजी है, DRL का रोल क्या? |News
10 months agoCNBC Awaaz.

Dr. Reddy’s Hits Life High On Reports Of Acquiring Novartis India

10 months agoBloomberg Quint

Novartis Starts ‘Strategic Review’ Of India Listed Business Amid Reports Of Sale Talks

10 months agoBloomberg Quint

Novartis India standalone net profit rises 161.40% in the September 2022 quarter

2 years agoBusiness Standard